Abstract 101P
Background
Immunotherapy has achieved breakthrough progress in non-small-cell lung cancer (NSCLC), with some patients experiencing long-term benefits. However, reliable tools for predicting the risk of disease progression (PD) in these patients are lacking. Circulating tumor DNA minimal residual disease (ctDNA MRD) has demonstrated predictive values in early-stage and locally advanced NSCLC, but its role in advanced NSCLC remains unclear.
Methods
The CR1STAL study (NCT05198154) is a multicenter prospective cohort study utilizing ctDNA MRD to monitor the risk of PD in advanced NSCLC. Patients with stage IIIB-IV NSCLC receiving first-line immunotherapy who had progression-free survival of 1 year were screened. Peripheral blood samples were collected every 2-3 months, synchronized with radiographic efficacy evaluations. The personalized target-capture panels for ctDNA detection were tailored based on individual tumor variants identified through the ultra-depth sequencing of a 1021-gene panel. A plasma sample with at least one detected variant was defined as ctDNA MRD positive.
Results
30 NSCLC patients were included, with a median age of 63.5 years. 86.7% were male with median follow-up time of 30.2 months (95% CI 28.4 to 32.0 months). Patients underwent ctDNA MRD monitoring with a median frequency of 4 assessments (range: 3 to 8). 50% of patients tested positive of ctDNA MRD. Compare with the negative group, the ctDNA MRD positive group exhibited an increased risk of PD (hazard ratio: 20.73, 95% CI 2.67 to 161.08, p=0.004), offering a median lead time of 6.2 months (95% CI 5.4 to 7.8 months) than radiographic progression. Furthermore, among the 13 patients who experienced PD, 12 were detected as ctDNA MRD positive, demonstrating a sensitivity of 92.3% and a positive predictive value of 80%. Among the 17 patients with non-PD, 14 were confirmed as ctDNA MRD negative, exhibiting a specificity of 82.4% and negative predictive value of 93.3%.
Conclusions
ctDNA MRD emerges a promising biomarker to predict the risk of PD in advanced NSCLC patients with long-term response to immunotherapy. The surveillance of ctDNA MRD enables earlier detection of PD and facilitates prompt intervention in high-risk patients.
Clinical trial identification
NCT05198154: ctDNA Analysis to Monitor the Risk of Progression after First-line lmmunotherapy in Patients with Advanced NSCLC (CR1STAL).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
41P - Cancer therapy-related cardiac dysfunction (CTRCD) after radiation therapy for breast cancer: Results of the French BACCARAT study
Presenter: Manoj Kumar Francois HONARYAR
Session: Poster session 07
Resources:
Abstract
42P - Correlation of circulating tumor cells with cancer stage
Presenter: Ana Paz
Session: Poster session 07
43P - A redesigned cell atlas of colon cancers to better assess their cellular composition
Presenter: Marine Sroussi
Session: Poster session 07
76P - Improving access to whole genome sequencing for patients with cancer of unknown primary using formalin-fixed paraffin embedded tissues and cell-free DNA
Presenter: Richard Tothill
Session: Poster session 07
77P - Whole-exome mutation profiling of cfDNA from over 2000 samples in major cancer indications
Presenter: Eric Jia
Session: Poster session 07
78P - Real-world analysis of actionable gene fusions identified by NGS and correlation with IHC in 422 patients from the community
Presenter: Husain Hatim
Session: Poster session 07
79P - Comprehensive genomic profiling provides patients access to novel matched therapies in a diverse real-world cohort of advanced lung cancer patients
Presenter: Jyoti Patel
Session: Poster session 07
80P - Development of a next-generation sequencing diagnostics recommender tool in the framework of the molecular tumor board Freiburg
Presenter: Ralf Mertes
Session: Poster session 07
81P - FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs – Preliminary data after two years of enrollment
Presenter: Katriina Jalkanen
Session: Poster session 07
82P - Clinical and molecular characteristics of gynecologic cancer patients in FINPROVE: The national phase II drug repurposing trial in Finland
Presenter: Anniina Färkkilä
Session: Poster session 07